Home -> Law Blog Directory -> Patent Law Blogs -> Philip Brooks’ Patent Infringement Updates
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Philip Brooks’ Patent Infringement UpdatesAriad Pharmaceuticals v. Eli Lilly
By Philip Brooks
The American Bar Association Section of Intellectual Property Law and the ABA Center for Continuing Legal Education are hosting a Teleconference and Live Audio Webcast on April 21, 2010 examining the written requirement for patentability.
Program Description
Join our expert faculty as they discuss the Federal Circuit?s recent en banc decision in Ariad v. Eli Lilly concerning the written description requirement under 35 U.S.C § 112. Among other topics, this panel will also discuss the implications of the Ariad decision and whether the case will be taken up by the Supreme Court. Additional topics to be discussed include:
- A general background on the written description requirement.
- The history of the Ariad case including the initial decision by the Federal Circuit three judge panel.
- The Federal Circuit?s application of the written description requirement over the years preceding Ariad.
- A discussion of the Ariad en banc decision and corresponding dissenting opinions.
Program Faculty
- Jonathan A. Muenkel (Moderator), Senior Associate, Jones Day
- Laura A. Coruzzi, Partner, Jones Day
- Christopher A. Cotropia, Professor of Law, University of Richmond School of Law
- Michael R. Dzwonczyk, Partner, Sughrue Mion
Registration and more details are available here.
Full post as published by Philip Brooks’ Patent Infringement Updates on April 14, 2010 (boomark / email).
Acura Pharmaceuticals, Inc. ACUR Securities Fraud
Acura Pharmaceuticals, Inc. ACUR
Zyprexa Settlement
Costs Lilly $1.4 Billion
Acura Pharmaceuticals, Inc. 401(k) / ERISA Stock Fraud
Acura Pharmaceuticals, Inc. 401(k) / ERISA Stock Fraud
Caraco Pharmaceuticals Laboratories
CPD
NPS Pharmaceuticals
Settles 2006 Class Action
Concentrated Acetaminophen Drops
Recalled by Brookstone Pharmaceuticals

Ariad v. Lilly: Ariad's Reply Brief
Ariad Files Petition for Rehearing in Ariad v. Lilly
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. (Fed. Cir. 2009)
Federal Circuit Grants En Banc Review in Ariad v. Lilly
Ariad plans appeal of loss in Amgen case in D. Del.
Ariad v. Lilly: Oral Argument - Addendum








